(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -3.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Arrowhead Pharmaceuticals's revenue in 2026 is $669,495,000.On average, 17 Wall Street analysts forecast ARWR's revenue for 2026 to be $66,648,095,165, with the lowest ARWR revenue forecast at $57,794,265,173, and the highest ARWR revenue forecast at $87,655,459,497. On average, 17 Wall Street analysts forecast ARWR's revenue for 2027 to be $43,886,350,352, with the lowest ARWR revenue forecast at $15,809,199,947, and the highest ARWR revenue forecast at $78,756,428,076.
In 2028, ARWR is forecast to generate $101,525,235,612 in revenue, with the lowest revenue forecast at $44,297,400,851 and the highest revenue forecast at $215,695,571,109.